Monitoring Agency Report for the quarter ended March 31, 2026
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suven Life Sciences has filed its Q4 FY2026 monitoring report for a Rs 857.64 crore preferential issue of convertible warrants (June 2025). CRISIL Ratings confirms fund utilization aligns with disclosed objects. Of the total proceeds, Rs 26.07 crore (30.4%) has been deployed so far, leaving Rs 59.70 crore unutilized. The company has invested unspent funds in mutual funds (Rs 22.12 crore) and fixed deposits with SBI (Rs 35 crore), earning Rs 7.78 crore in returns. Clinical development through subsidiary Suven Neurosciences has consumed Rs 18.88 crore, while R&D and new R&D centre CAPEX show slower deployment at Rs 4.04 crore and Rs 0.30 crore respectively. Rs 9,331.50 lakh from warrant exercise remains pending and will be received by December 2026.
The filing confirms orderly utilization of equity proceeds with no deviations from stated objects. The significant unutilized balance parked in liquid instruments provides flexibility but the very low R&D centre spend (1.5%) may raise questions about capital deployment timelines. No red flags for shareholders regarding fund mismanagement.